Showing results (31-40 of 180) with videos related to
Sort By:
Pageof 18
Multiple Sclerosis International|November 19, 2011
Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a reviewMazen Abu-Mugheisib, Reiner Benecke, Uwe K ZettlCurrent Opinion in Neurology|May 7, 2020
Prevention and management of adverse effects of disease modifying treatments in multiple sclerosisLucia Moiola, Paulus S Rommer, Uwe K ZettlJournal of Neurology|March 21, 2009
Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitationsEilhard Mix, Hans Meyer-Rienecker, Uwe K ZettlJournal of Neurology|March 21, 2009
Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networksRobert H Goertsches, Michael Hecker, Uwe K ZettlPharmacogenomics|April 1, 2011
Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapyRobert H Goertsches, Uwe K Zettl, Michael HeckerCurrent Pharmaceutical Design|September 23, 2021
Headache in Multiple Sclerosis - Pharmacological AspectsMarcel Gebhardt, Peter Kropp, Frank Hoffmann, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|December 4, 2018
Headache in the course of multiple sclerosis: a prospective studyMarcel Gebhardt, Peter Kropp, Frank Hoffmann, et al.Current Pharmaceutical Design|September 24, 2004
Transcription factors in autoimmune diseasesMartin Eggert, Andreas Klüter, Uwe K Zettl, et al.Journal of Neurology|May 16, 2007
Transcranial brain sonography findings related to neuropsychological impairment in multiple sclerosisUwe Walter, Sebastian Horowski, Reiner Benecke, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 3, 2013
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)Uwe K Zettl, Thomas Henze, Ute Essner, et al.Pageof 18